A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Schroeder Mark A.; Fiala Mark A.; Huselton Eric; Cardone Michael H.; Jaeger Savina; Jean Sae Rin; Shea Kathryn; Ghobadi Armin; Wildes Tanya; Stocked-Goldstein Keith E.; Vij Ravi

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

【24h】

A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

机译：用于治疗复发/难治多骨髓瘤的Carfilzomib，Pegymated脂质体Doxorubicin和地塞米松的I / II试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Pegylated liposomal doxorubicin (PLD) combined with bortezomib is an effective salvage regimen for relapsed refractory multiple myeloma (RRMM). Carfilzomib, a second-generation proteasome inhibitor, has clinical efficacy even among bortezomib-refractory patients.

机译：目的：聚乙二醇化脂质体DOXORUBICIN（PLD）与Bortezomib合并是一种有效的耐火性多发性骨髓瘤（RRMM）的救助方案。即使在硼氮螨虫 - 难治患者中，Carfilzomib是第二代蛋白酶体抑制剂，也具有临床疗效。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research 》 |2019年第13期| 共8页
作者
Schroeder Mark A.; Fiala Mark A.; Huselton Eric; Cardone Michael H.; Jaeger Savina; Jean Sae Rin; Shea Kathryn; Ghobadi Armin; Wildes Tanya; Stocked-Goldstein Keith E.; Vij Ravi;
展开▼
作者单位

Washington Univ Sch Med BMT &

Leukemia Program St Louis MO 63110 USA;

Washington Univ Sch Med BMT &

Leukemia Program St Louis MO 63110 USA;

Univ Rochester Med Ctr Hematol Oncol Div Rochester NY 14642 USA;

Eutrop Pharmaceut Cambridge MA USA;

Eutrop Pharmaceut Cambridge MA USA;

Eutrop Pharmaceut Cambridge MA USA;

Eutrop Pharmaceut Cambridge MA USA;

Washington Univ Sch Med BMT &

Leukemia Program St Louis MO 63110 USA;

Washington Univ Sch Med BMT &

Leukemia Program St Louis MO 63110 USA;

Washington Univ Sch Med BMT &

Leukemia Program St Louis MO 63110 USA;

Washington Univ Sch Med BMT &

Leukemia Program St Louis MO 63110 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma [J] . Schroeder Mark A., Fiala Mark A., Huselton Eric, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019 ,第13期

机译：用于治疗复发/难治多骨髓瘤的Carfilzomib，Pegymated脂质体Doxorubicin和地塞米松的I / II试验
2. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. [J] . Chanan Khan A, Miller KC, Musial L Leukemia and lymphoma . 2009 ,第7期

机译：硼替佐米联合聚乙二醇化脂质体阿霉素和沙利度胺对复发或难治性多发性骨髓瘤患者是一种有效的类固醇独立治疗方案：II期临床试验的结果。
3. Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma [J] . LazaryanA., HusseinM.A., ReuF.J., American Journal of Hematology . 2014 ,第4期

机译：MM-011的成熟结果：脂质体阿霉素，长春新碱，地塞米松和来那度胺联合治疗，然后来那度胺维持治疗复发/难治性多发性骨髓瘤的I / II期试验
4. Proteomic alterations caused by treatment with Bortezomib, Doxorubicin, and Dexamethasone in Myeloma [C] . Dominik Dytfeld, Vadiraja B. Bhat, Malathi Hari, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：用髓质族，多柔比星和地塞米松治疗引起的蛋白质组学改变
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. The MUK five protocol: a phase II randomised controlled parallel group multi-centre trial of carfilzomib cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma [O] . Sarah Brown, Samantha Hinsley, Mónica Ballesteros, 2016

机译：MUK五种方案：卡非佐米环磷酰胺和地塞米松（CCD）与环磷酰胺硼替佐米（Velcade）和地塞米松（CVD）的II期随机对照平行组多中心试验用于首次复发和原发性难治性多发性骨髓瘤
7. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma [O] . J R Berenson, O Yellin, T Kazamel, 2012

机译：用于复发/难治多骨髓瘤的患者的聚乙二醇化脂质体DOXORUBICIN，硼化族，地塞米松和Lenalidomide的2阶段研究

A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

摘要

著录项

相似文献

相关主题

期刊订阅